Also, analysis of an independent dataset from The Cancer Genome Atlas (TCGA) revealed the significant correlation between higher SOX10 expression with the reduced overall survival (3 and 5 years) of glioma patients (n = 103), and the median survival for patients with high SOX10 expression was 2051 days, shorter than that (2432 days) for patients with low SOX10 expression (Fig. 1E). This evidence concerns the gene SOX10 and central nervous system cancer.